Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Tumors Clear all
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

NCT02431260
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB054329 Monotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720
View directory record Official record
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Eflapegrastim, Chemotherapy
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042
View directory record Official record
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00052273
View directory record Official record
Conditions
Adult, Solid Tumor
Interventions
capecitabine, enzastaurin hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting No phase listed Observational

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

NCT06295965
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Malignant Solid Neoplasm, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis, Idiopathic Cytopenia of Undetermined Significance, Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder, Ovarian Carcinoma, Myeloid Neoplasm Post Cytotoxic Therapy
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
Biological · Procedure · Other
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

NCT00437372
View directory record Official record
Conditions
Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms
Interventions
Sunitinib, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting Phase 1 Interventional

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

NCT07030712
View directory record Official record
Conditions
Metastatic Neoplasm
Interventions
MK-8294, CD8 PET Tracer
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional Results available

A Study of DS-2248 in Participants With Advanced Solid Tumors

NCT01288430
View directory record Official record
Conditions
Solid Tumors, Non-small Cell Lung Carcinoma
Interventions
DS-2248
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Duarte, California • Loma Linda, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

NCT04902144
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sequim, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 24, 2026, 10:04 PM EDT
Active, not recruiting Phase 1 Interventional

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367
View directory record Official record
Conditions
Metastatic Solid Tumors, Advanced Solid Tumors
Interventions
MK-0472, Pembrolizumab, MK-1084
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Louisville, Kentucky • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NCT03977467
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Solid Tumor
Interventions
Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 24, 2026, 10:04 PM EDT
Not listed Not applicable Interventional

Dietary Soy Isoflavones for the Prevention of Cancer

NCT00003100
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
soy isoflavones
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00085553
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tipifarnib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

NCT00782002
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-18F1
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Early Phase 1 Interventional

PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy

NCT01666353
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma (RCC), Non-small Cell Lung Cancer (NSCLC)
Interventions
PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

NCT00251407
View directory record Official record
Conditions
Solid Tumor
Interventions
Taxotere, Cisplatin, CPT-11
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 24, 2026, 10:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
Interventions
23ME-00610
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
12 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

NCT00980239
View directory record Official record
Conditions
Liver Cancer, Advanced Cancer
Interventions
Irinotecan, Bevacizumab, Oxaliplatin, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 24, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting

NCT07126301
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Aromatherapy and Essential Oils, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 24, 2026, 10:04 PM EDT
Active, not recruiting Not applicable Interventional Results available

Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

NCT04409236
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Quit2Heal, QuitGuide, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

NCT04050709
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Interventions
PD-L1 t-haNK
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 24, 2026, 10:04 PM EDT